Advertisement

Topics

vTv Therapeutics Reports 2016 Fourth Quarter and Full Year Financial and Operational Results and Recent Highlights

18:15 EST 27 Feb 2017 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
Completed enrollment of Part A pivotal Phase 3 STEADFAST Study of azeliragon in Alzheimer’s Disease Positive Phase 2 results for Type 2 diabetes therapies, TTP273 and TTP399 vTv Therapeutics Inc. (vTv) (Nas...

Other Sources for this Article

vTv Therapeutics Inc.
Michael Gibralter, 646-378-2938
IR@vtvtherapeutics.com
or
Media:
Pure Communications Inc.
Katie Engleman, 910-509-3977
Katie@purecommunicationsinc.com

NEXT ARTICLE

More From BioPortfolio on "vTv Therapeutics Reports 2016 Fourth Quarter and Full Year Financial and Operational Results and Recent Highlights"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Neurology - Central Nervous System (CNS)
Alzheimer's Disease Anesthesia Anxiety Disorders Autism Bipolar Disorders Dementia Epilepsy Multiple Sclerosis (MS) Neurology Pain Parkinson's Disease Sleep Disorders Neurology is the branch of me...